Life Sciences
|
DOI: 10.17160/josha.5.5.436
JOSHA`s CRITICAL REVIEW OF „Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer”
R
Roland Mertelsmann, Gerhard G. Steinmann
Albert-Ludwigs Universität
A striking benefit in overall survival was observed, and a less striking benefit in progression-free survival. This is quite in contrast to other recent studies with checkpoint inhibitors demonstrating a…